ID: ALA206191

Max Phase: Preclinical

Molecular Formula: C27H38N4O7

Molecular Weight: 530.62

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCC[C@H](NC(=O)O[C@@H]1C(=O)N(C(=O)N2CCOCC2)CC1(C)C)C(=O)C(=O)N[C@H](C)c1ccccc1

Standard InChI:  InChI=1S/C27H38N4O7/c1-5-6-12-20(21(32)23(33)28-18(2)19-10-8-7-9-11-19)29-25(35)38-22-24(34)31(17-27(22,3)4)26(36)30-13-15-37-16-14-30/h7-11,18,20,22H,5-6,12-17H2,1-4H3,(H,28,33)(H,29,35)/t18-,20+,22-/m1/s1

Standard InChI Key:  RCFQCZHEISPYRY-KAGYGMCKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 530.62

Molecular Weight (Monoisotopic): 530.2740

AlogP: 2.41

#Rotatable Bonds: 9

Polar Surface Area: 134.35

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 12.24

CX Basic pKa:

CX LogP: 2.97

CX LogD: 2.97

Aromatic Rings: 1

Heavy Atoms: 38

QED Weighted: 0.47

Np Likeness Score: -0.42

References

1. Barrett DG, Catalano JG, Deaton DN, Hassell AM, Long ST, Miller AB, Miller LR, Ray JA, Samano V, Shewchuk LM, Wells-Knecht KJ, Willard DH, Wright LL..  (2006)  Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.,  16  (6): [PMID:16376075] [10.1016/j.bmcl.2005.11.101]

Source

Source(1):

• Scientific Literature